These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 23744708

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
    Lawrence CL, Pollard CE, Hammond TG, Valentin JP.
    J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
    [Abstract] [Full Text] [Related]

  • 3. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
    Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG.
    Cardiovasc Res; 2003 Apr 01; 58(1):32-45. PubMed ID: 12667944
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity.
    De Clerck F, Van de Water A, D'Aubioul J, Lu HR, van Rossem K, Hermans A, Van Ammel K.
    Fundam Clin Pharmacol; 2002 Apr 01; 16(2):125-40. PubMed ID: 12031065
    [Abstract] [Full Text] [Related]

  • 6. A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the ion works HTTM system.
    Guthrie H, Livingston FS, Gubler U, Garippa R.
    J Biomol Screen; 2005 Dec 01; 10(8):832-40. PubMed ID: 16234341
    [Abstract] [Full Text] [Related]

  • 7. New in vitro model for proarrhythmia safety screening: IKs inhibition potentiates the QTc prolonging effect of IKr inhibitors in isolated guinea pig hearts.
    Kui P, Orosz S, Takács H, Sarusi A, Csík N, Rárosi F, Csekő C, Varró A, Papp JG, Forster T, Farkas AS, Farkas A.
    J Pharmacol Toxicol Methods; 2016 Dec 01; 80():26-34. PubMed ID: 27063345
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk.
    Wible BA, Hawryluk P, Ficker E, Kuryshev YA, Kirsch G, Brown AM.
    J Pharmacol Toxicol Methods; 2005 Dec 01; 52(1):136-45. PubMed ID: 15950494
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies.
    Shah RR.
    Novartis Found Symp; 2005 Dec 01; 266():251-80; discussion 280-5. PubMed ID: 16050273
    [Abstract] [Full Text] [Related]

  • 12. Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety.
    Gintant GA, Su Z, Martin RL, Cox BF.
    Toxicol Pathol; 2006 Dec 01; 34(1):81-90. PubMed ID: 16507548
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade.
    Deacon M, Singleton D, Szalkai N, Pasieczny R, Peacock C, Price D, Boyd J, Boyd H, Steidl-Nichols JV, Williams C.
    J Pharmacol Toxicol Methods; 2007 Dec 01; 55(3):238-47. PubMed ID: 17141530
    [Abstract] [Full Text] [Related]

  • 16. Beat-to-beat variability of repolarization as a new biomarker for proarrhythmia in vivo.
    Varkevisser R, Wijers SC, van der Heyden MA, Beekman JD, Meine M, Vos MA.
    Heart Rhythm; 2012 Oct 01; 9(10):1718-26. PubMed ID: 22609158
    [Abstract] [Full Text] [Related]

  • 17. Monophasic action potential in anaesthetized guinea pigs as a biomarker for prediction of liability for drug-induced delayed ventricular repolarization.
    Tabo M, Kimura K, Ito S.
    J Pharmacol Toxicol Methods; 2007 Oct 01; 55(3):254-61. PubMed ID: 17229580
    [Abstract] [Full Text] [Related]

  • 18. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.
    De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N.
    Drug Saf; 2002 Oct 01; 25(4):263-86. PubMed ID: 11994029
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Choice of cardiac tissue plays an important role in the evaluation of drug-induced prolongation of the QT interval in vitro in rabbit.
    Lu HR, Vlaminckx E, Teisman A, Gallacher DJ.
    J Pharmacol Toxicol Methods; 2005 Oct 01; 52(1):90-105. PubMed ID: 15978848
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.